Multidrug-Resistant Infections and Outcome of Critically Ill Patients with Coronavirus Disease 2019: A Single Center Experience
Karruli et al.
, Multidrug-Resistant Infections and Outcome of Critically Ill Patients with Coronavirus Disease 2019: A Single..
, Microbial Drug Resistance, doi:10.1089/mdr.2020.0489
Retrospective 32 ICU patients, showing no significant difference with HCQ treatment in unadjusted results.
This study is excluded in the after exclusion results of meta
unadjusted results with no group details.
risk of death, 4.8% lower, RR 0.95, p = 1.00, treatment 20 of 28 (71.4%), control 3 of 4 (75.0%), NNT 28.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Karruli et al., 1 Sep 2021, retrospective, Italy, peer-reviewed, 13 authors, study period March 2020 - May 2020.
Abstract: MICROBIAL DRUG RESISTANCE
Volume 27, Number 9, 2021
ª Mary Ann Liebert, Inc.
Multidrug-Resistant Infections and Outcome
of Critically Ill Patients with Coronavirus Disease 2019:
A Single Center Experience
Arta Karruli,1 Filomena Boccia,1 Massimo Gagliardi,1 Fabian Patauner,1 Maria Paola Ursi,1 Pino Sommese,1
Rosanna De Rosa,2 Patrizia Murino,2 Giuseppe Ruocco,3 Antonio Corcione,2 Roberto Andini,4
Rosa Zampino,4,5 and Emanuele Durante-Mangoni1,4
Background: The aim of this study was to assess the drivers of multidrug-resistant (MDR) bacterial infection
development in coronavirus disease 2019 (COVID-19) and its impact on patient outcome.
Methods: Retrospective analysis on data from 32 consecutive patients with COVID-19, admitted to our intensive
care unit (ICU) from March to May 2020. Outcomes considered were MDR infection and ICU mortality.
Results: Fifty percent of patients developed an MDR infection during ICU stay after a median time of 8 [4–11]
days. Most common MDR pathogens were carbapenem-resistant Klebsiella pneumoniae and Acinetobacter
baumannii, causing bloodstream infections and pneumonia. MDR infections were linked to a higher length of
ICU stay ( p = 0.002), steroid therapy ( p = 0.011), and associated with a lower ICU mortality (odds ratio: 0.439,
95% confidence interval: 0.251–0.763; p < 0.001). Low-dose aspirin intake was associated with both MDR
infection ( p = 0.043) and survival ( p = 0.015). Among MDR patients, mortality was related with piperacillintazobactam use ( p = 0.035) and an earlier onset of MDR infection ( p = 0.042).
Conclusions: MDR infections were a common complication in critically ill COVID-19 patients at our center.
MDR risk was higher among those dwelling longer in the ICU and receiving steroids. However, MDR infections were not associated with a worse outcome.
Keywords: MDR, COVID-19, SARS-CoV-2, ICU, outcome
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.